Latest News & Updates

Breaking News

  • 6 hours ago

  • Pharma Now Editorial Team

LIXTE Biotechnology Pivots to AI Energy Infrastructure, Appoints Denham Capital Founder to Board
Breaking News
T-CURX Acquires Pantherna to Accelerate Non-Viral In Vivo CAR-T Program by One Year

Pharma Now Editorial Team

Other trending news you may like to read

LIXTE Biotechnology Pivots to AI Energy Infrastructure, Appoints Denham Capital Founder to Board

LIXTE Biotechnology exits pharma to become an AI energy infrastructure platform, appointing Denham Capital founder Stuart Porter to its board.

Pharma Now Editorial Team

Pharma Now

T-CURX Acquires Pantherna to Accelerate Non-Viral In Vivo CAR-T Program by One Year

T-CURX acquires Pantherna's LNP delivery platform, pulling its non-viral in vivo CAR-T program one year closer to clinical trials.

Pharma Now Editorial Team

Pharma Now

IDEAYA Biosciences and Servier File NDA Under RTOR for Darovasertib Combination in Metastatic Uveal Melanoma

IDEAYA and Servier target H2 2026 NDA filing under FDA's RTOR program after OptimUM-02 meets primary PFS endpoint in metastatic uveal melanoma.

Pharma Now Editorial Team

Pharma Now

Renexxion and Dr. Falk Pharma Advance Naronapride into Phase 3 Targeting US NDA and EU Approval

Renexxion and Dr. Falk Pharma advance naronapride into Phase 3 pivotal studies, targeting a US NDA and parallel EU approval for gastroparesis.

Pharma Now Editorial Team

Pharma Now